BioSpace News Archive

CureMD, a leading provider of comprehensive technology solutions for community oncology, is proud to announce its partnership with Tempus, a leader in artificial intelligence and precision medicine, to integrate Tempus’ advanced genomic testing capabilities into CureMD’s cutting-edge Electronic Health Record (EHR) system.

Levita Magnetics, whose mission is to help more patients get access to better surgery, announced today it has received U.S. Food and Drug Administration (FDA) clearance for its MARS™ platform.

Catalent, Inc. announced that it will release financial results for the fourth quarter of fiscal year 2023 ended June 30, 2023, before the market open on Tuesday, August 29, 2023.

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into a clinical trial collaboration and supply agreement with Bayer AG for Celcuity’s Phase 1b/2 clinical trial of gedatolisib and Nubeqa® (darolutamide) in patients with metastatic castration resistant prostate cancer (mCRPC).

Lifecore Biomedical, Inc. announced that it received a notice on August 17, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250 because the Company failed to timely file its Annual Report on Form 10-K for the period ended May 28, 2023 with the Securities and Exchange Commission.

Evofem Biosciences, Inc. announced it has signed a confidential non-binding letter of intent relating to a possible merger with a publicly-traded entity which, if consummated, could result in Evofem being listed on a national stock exchange.

Elicio Therapeutics announced that on August 21, 2023, the Company’s board of directors approved the grant of 72,980 inducement stock options to two new employees, as an inducement material to each employee entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare events of retinal vasculitis reported in real-world treatment with SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Zimmer Biomet Holdings, Inc. today announced the appointment of Ivan Tornos as President and Chief Executive Officer (CEO) and election to the Board of Directors, effective immediately.

Verismo Therapeutics , a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced that it had entered into a licensing agreement with the University of Pennsylvania.